122 related articles for article (PubMed ID: 38554347)
41. An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis.
Wang KC; Chang WH; Lee WL; Huang N; Huang HY; Yen MS; Guo CY; Wang PH
BMC Cancer; 2014 Nov; 14():831. PubMed ID: 25403543
[TBL] [Abstract][Full Text] [Related]
42. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
Okunade KS; Dawodu O; Adenekan M; Nwogu CM; Awofeso O; Ugwu AO; Salako O; John-Olabode S; Olowoselu OF; Anorlu RI
Niger J Clin Pract; 2020 Aug; 23(8):1141-1147. PubMed ID: 32788493
[TBL] [Abstract][Full Text] [Related]
43. Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
Chen S; Tai H; Tong X; Wang J; Yang F; Yang Y; Yiqin O
J Obstet Gynaecol Res; 2014 Sep; 40(9):2058-65. PubMed ID: 25181626
[TBL] [Abstract][Full Text] [Related]
44. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
Paek J; Lee M; Nam EJ; Kim SW; Kim YT
Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
[TBL] [Abstract][Full Text] [Related]
45. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
46. [Establishment and application of a nomogram model for prognostic risk prediction in patients with epithelial ovarian cancer].
Li Z; Cai XW; Yan P; Zhou D; He MM; Deng L; Wang YZ; Liang ZQ
Zhonghua Fu Chan Ke Za Zhi; 2022 Mar; 57(3):190-197. PubMed ID: 35385956
[No Abstract] [Full Text] [Related]
47. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
48. Incidence of and risk factors associated with lung metastases in newly diagnosed epithelial ovarian cancer with a look on prognosis after diagnosis: a population-based cohort study of the SEER database.
Xu J; Hussain I; Wang L; Deng K; Zhao L; Zhou K; Zhang L; Xu Z; Li K
Arch Gynecol Obstet; 2021 Oct; 304(4):1007-1020. PubMed ID: 33635405
[TBL] [Abstract][Full Text] [Related]
49. MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer.
Wang X; Meng X; Li H; Liu W; Shen S; Gao Z
Clin Transl Oncol; 2014 Nov; 16(11):954-8. PubMed ID: 24696291
[TBL] [Abstract][Full Text] [Related]
50. Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014.
Wu SG; Li FY; Lei J; Hua L; He ZY; Zhou J
Med Sci Monit; 2020 Feb; 26():e920531. PubMed ID: 32008036
[TBL] [Abstract][Full Text] [Related]
51. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
Mardas M; Stelmach-Mardas M; Madry R
Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
[TBL] [Abstract][Full Text] [Related]
52. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.
Jeong SY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS; Lee YY
J Ovarian Res; 2019 Dec; 13(1):1. PubMed ID: 31892329
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
54. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
[TBL] [Abstract][Full Text] [Related]
55. Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria.
Okunade KS; Adejimi AA; Ohazurike EO; Salako O; Osunwusi B; Adenekan MA; Ugwu AO; Soibi-Harry A; Dawodu O; Okunowo AA; Anorlu RI; Berek JS
JCO Glob Oncol; 2021 Jan; 7():89-98. PubMed ID: 33449803
[TBL] [Abstract][Full Text] [Related]
56. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
[TBL] [Abstract][Full Text] [Related]
57. [Pathological characteristics and prognosis of 664 patients with epithelial ovarian cancer: a retrospective analysis].
Hou MM; Chen Y; Wu YK; Xi MR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):859-62, 875. PubMed ID: 25341355
[TBL] [Abstract][Full Text] [Related]
58. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
59. Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
Sun S; Cai J; Yang Q; Zhu Y; Zhao S; Wang Z
PLoS One; 2016; 11(11):e0166058. PubMed ID: 27812204
[TBL] [Abstract][Full Text] [Related]
60. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
